Menu Search
Equities

Alexion Pharmaceuticals Inc

ALXN:DEU

Alexion Pharmaceuticals Inc

Actions
  • Price (EUR)137.40
  • Today's Change-0.96 / -0.69%
  • Shares traded0.00
  • 1 Year change+42.38%
  • Beta--
Data delayed at least 15 minutes, as of Apr 21 2021 08:31 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

  • Revenue in USD (TTM)6.07bn
  • Net income in USD603.40m
  • Incorporated1992
  • Employees3.84k
  • Location
    Alexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
  • Phone+1 (475) 230-2596
  • Fax+1 (203) 271-8198
  • Websitehttps://alexion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALXN:NSQ since
announced		Transaction
value
Portola Pharmaceuticals IncDeal completed05 May 202005 May 2020Deal completed60.38%1.46bn
Data delayed at least 15 minutes, as of Apr 20 2021 21:00 BST.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.